GlassScriptPhysician profile
Rizwan Ahmed
NPI 1841469061
$3,413.86
in general payments reported to CMS, 2019-2025
24 companies · $807 in 2025
The $807 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $632 · 2020: $174 · 2021: $194 · 2022: $511 · 2023: $454 · 2024: $642 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,861 · Education: $41.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,860.87 |
| Education | $41.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,197.90 | 2019-2025 | Skyrizi, Rinvoq, Viberzi |
| Janssen Scientific Affairs, LLC | $348.98 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $254.00 | 2019-2024 | Entyvio, Gattex |
| Janssen Biotech, INC. | $218.87 | 2019-2025 | Stelara, Tremfya |
| Medtronic, INC. | $185.64 | 2022-2023 | Hawkone |
| Pfizer INC. | $155.27 | 2019-2025 | |
| Kerecis Limited | $139.54 | 2019-2022 | |
| Intuitive Surgical, INC. | $126.59 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $88.45 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.54 | 2019-2025 | Xifaxan |
| Celgene Corporation | $81.97 | 2023-2024 | Zeposia |
| Genzyme Corporation | $80.30 | 2025 | |
| Celltrion USA INC. | $70.88 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Regeneron Healthcare Solutions, INC. | $66.05 | 2024 | Dupixent |
| Ardelyx, INC. | $65.95 | 2025 | Ibsrela |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $61.02 | 2024-2025 | Omvoh |
| Boston Scientific Corporation | $52.66 | 2021 | |
| Madrigal Pharmaceuticals | $33.98 | 2025 | Rezdiffra |
| Ethicon US, LLC | $20.33 | 2024 | Linx Reflux Management System |
| Ucb, INC. | $19.33 | 2019 | |
| Alnylam Pharmaceuticals INC. | $17.97 | 2023 | Givlaari |
| Azurity Pharmaceuticals, INC. | $17.35 | 2025 | Suflave |
| Ironwood Pharmaceuticals, INC | $15.92 | 2019 | |
| Allergan, INC. | $12.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rizwan Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.